However, osimertinib has now become the standard of care for the first-line treatment of EGFR-mutant NSCLC [8,14] and it was recently approved for use in the adjuvant setting following tumor resection in patients with EGFR-mutant NSCLC [15]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.